CytoDyn Files FDA for COVID-19 treatment CYCY upover 46% on news ...
VANCOUVER, Washington, March 27, 2020 (GLOBE NEWSWIRE) --
CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the suggestion of the U.S. Food and Drug Administration (FDA), the Company filed another round of modifications to its IND and protocol for a Phase 2 clinical trial with leronlimab (PRO 140). In addition, the FDA suggested the Company file a second randomized protocol for all COVID-19 patients in severe condition, so as to preclude each physician from filing an emergency IND for every patient to be treated with leronlimab.
https://finance.yahoo.com/news/cytodyn-files-fda-suggested-modifications-101510223.html -LT